Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 7640
117th Congress(2021-2022)
To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Introduced
Introduced
Introduced in House on May 3, 2022
Overview
Text
Introduced in House 
May 3, 2022
No Linkage Found
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(May 3, 2022)
May 3, 2022
No Linkage Found
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 7640 (Introduced-in-House)


117th CONGRESS
2d Session
H. R. 7640


To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).

IN THE HOUSE OF REPRESENTATIVES

May 3, 2022

Mr. Bilirakis (for himself and Mr. Butterfield) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Reauthorization of grants and contracts for development of orphan drugs.

Section 5(c) of the Orphan Drug Act (21 U.S.C. 360ee(c)) is amended by striking “2018 through 2022” and inserting “2023 through 2027”.